Christopher Mirabelli Ph.D Overview
- Company
- Leap Therapeutic...
- Primary Position
-
Chairman
- Primary Industry
-
Healthcare
- Active Board Seats
-
3
- Med. Deal Size
-
- Med. Valuation
-
Christopher Mirabelli Ph.D General Information
Biography
Dr. Christopher Mirabelli serves as Chairman at Leap Therapeutics. He also serves as a Independent Advisory Committee member at Longview Healthcare Ventures. He serves as Chairman at Flamingo Therapeutics. He served as Chief Executive Officer and President at DecImmune Therapeutics. He serves as a Board Member at Aro Biotherapeutics. He has served as the Chairman of our Board of Directors since 2016 and has also served as our President and Chief Executive Officer since our inception in 2011. He has been a managing director of HealthCare Ventures LLC since 2000. From December 1999 to May 2000, he served as president of pharmaceutical research and development and member of the board of directors of Millennium Pharmaceuticals, Inc., following its merger with LeukoSite Inc., where he had been serving as president, chief executive officer and chairman of the board of directors since 1993. He was a co-founder of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), where he held several positions including senior vice president of research, from 1989 until 1993. He started his career at SmithKline and French Laboratories (now part of GlaxoSmithKline Plc) R&D Division. He served as Board Member at Theraclone Sciences and Dynacure and as Managing Director at HealthCare Ventures. He also served as Chief Executive Officer, President and Board Member at Anexon. He was Chairman of the Board and Chief Executive Officer of LeukoSite, Inc. from 1993 through 1999. Before joining Leukosite, he was a co-founder and Executive Vice President of Isis Pharmaceuticals (now Ionis). He was previously with SmithKline and French Laboratories R&D Division. He is a member of the board of advisors of the Accelerator Fund at Harvard Medical School, an initiative that identifies and funds translation of early-stage medical discoveries to preclinical proof-of-concept. He received his Doctor of Philosophy degree in Molecular Pharmacology from Baylor College of Medicine. He served as President & Board Member at Apofore. He is a member of the board of advisors of the Blavatnik Biomedical Accelerator Fund at Harvard Medical School and the Boston Biomedical Innovation Center. He is a member of the Board of Trustees of Guilford College. He received his Ph.D. in molecular pharmacology from Baylor College of Medicine and a B.S. degree in biology from State University of New York at Fredonia.
Contact Information
Address
- 47 Thorndike Street
- Suite B1-1
- Cambridge, MA 02141
- United States
Christopher Mirabelli Ph.D Positions (2)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Flamingo Therapeutics | Company | Chairman | Leuven, Belgium | Drug Discovery | |
HealthCare Ventures | Investor | Managing Director | Cambridge, MA | Venture Capital |
Christopher Mirabelli Ph.D Board Seats (4)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
Aro Biotherapeutics | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Philadelphia, PA | |
Dynacure | Drug Discovery | Acquired/Merged | Formerly VC-backed | France | |
Flamingo Therapeutics | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Leuven, Belgium | |
Leap Therapeutics | Biotechnology | Publicly Held | Formerly VC-backed | Cambridge, MA |
Christopher Mirabelli Ph.D Lead Partner on Deals (23)
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
MacroCure | 23-Jan-2017 | Merger/Acquisition | Completed | Biotechnology | Radnor, PA | |
Proteostasis Therapeutics | 08-Sep-2015 | Completed | Drug Discovery | Boston, MA | ||
Galleon Pharmaceuticals | 11-Jun-2015 | Completed | Pharmaceuticals | Horsham, PA | ||
Theraclone Sciences | 12-Aug-2013 | Completed | Drug Delivery | Seattle, WA | ||
Trevena | 10-May-2013 | Completed | Drug Discovery | Chesterbrook, PA | ||
DecImmune Therapeutics | 26-Feb-2013 | Completed | Drug Discovery | Cambridge, MA | ||
Galleon Pharmaceuticals | 24-Jan-2012 | Completed | Pharmaceuticals | Horsham, PA | ||
Apofore | 01-Aug-2011 | Completed | Pharmaceuticals | Cambridge, MA | ||
Proteostasis Therapeutics | 01-Dec-2010 | Early Stage VC | Completed | Drug Discovery | Boston, MA | |
DecImmune Therapeutics | 17-Sep-2010 | Later Stage VC | Completed | Drug Discovery | Cambridge, MA |
Christopher Mirabelli Ph.D Network (204)
Board Members (94)
Name | Company | Representing | Location | From |
---|---|---|---|---|
Ohad Hammer | Dynacure | Pontifax Venture Capital | France | |
Monica Bertagnolli | Leap Therapeutics | Self | Cambridge, MA | |
Aro Biotherapeutics | Self | Philadelphia, PA | ||
Dynacure | Self | France | ||
Flamingo Therapeutics | Participatiemaatschappij Vlaanderen | Leuven, Belgium |
Portfolio Executives (104)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
Michelle Marcelino | MacroCure | Director, Clinical Operations | 23-Jan-2017 | Radnor, PA |
Uplaksh Kumar Ph.D | MacroCure | Vice President, Global Operations | 23-Jan-2017 | Radnor, PA |
MacroCure | President & Co-Chief Executive Officer | 23-Jan-2017 | Radnor, PA | |
MacroCure | Co-Chief Executive Officer | 23-Jan-2017 | Radnor, PA | |
MacroCure | Chief Financial Officer | 23-Jan-2017 | Radnor, PA |
Fund Team Members (6)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Douglas Onsi JD | HealthCare Ventures | HealthCare Ventures VIII | Cambridge, MA |
Douglas Onsi JD | HealthCare Ventures | HealthCare Ventures IX | Cambridge, MA |
HealthCare Ventures | Cambridge, MA | ||
HealthCare Ventures | Cambridge, MA | ||
HealthCare Ventures | Cambridge, MA |
Christopher Mirabelli Ph.D Affiliated Funds (3)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
HealthCare Ventures VI | HealthCare Ventures | Venture - General | Fully Invested | 2002 | ||||
HealthCare Ventures VIII | HealthCare Ventures | Venture - General | Closed | 2005 | ||||
HealthCare Ventures IX | HealthCare Ventures | Venture - General | Closed | 2010 |
Christopher Mirabelli Ph.D Advisory Roles (1)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Longview Healthcare Ventures | Investor | Independent Advisory Committee Member | Boston, MA | Venture Capital |
Christopher Mirabelli Ph.D FAQs
-
Who is Christopher Mirabelli Ph.D?
Dr. Christopher Mirabelli serves as Chairman at Leap Therapeutics.
-
How much does Christopher Mirabelli Ph.D typically invest?
Christopher Mirabelli Ph.D's median deal size is
. -
What is Christopher Mirabelli Ph.D’s main position?
Christopher Mirabelli Ph.D’s primary position is Chairman.
-
How many active board seats does Christopher Mirabelli Ph.D hold?
Christopher Mirabelli Ph.D holds 4 board seats including Aro Biotherapeutics, Dynacure, Flamingo Therapeutics, and Leap Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »